Isoray, Inc. (ISR) is the manufacturer of Cesium Blu or Cesium-131 brachytherapy seeds. It develops and markets isotope-based products for treating different types of cancers. Cesium Blu is utilized for the treatment of prostate, head, lungs, colorectal and pelvic-related cancer.
The price of ISR stock in the early trading on March 2, 2022, was last checked to be $0.35 with a surge of 3.82%.
ISR: Events and Happenings
On March 02, 2022, ISR announced that the researchers from Pittsburgh University’s School of Medicine have publicized a research study that determined the outstanding results on prostate cancer patients. The patients were treated with Cesium- Blu. The peer-reviewed publication titled ‘Treatment of prostate cancer with Cs-131: Long term results from a single institution’, was published in BRACHYTHERAPY.
ISR: Key Financials
On February 8, 2022, ISR released its consolidated financial statement for the second fiscal quarter of 2022 ended December 31, 2021. Some of the key features are discussed below.
Revenue
Revenue in Q2 2022 was $2.82 million comparable to $2.36 million in the prior-year period. The company observed a development of 19% in revenue over the year. Also, it topped the revenue estimates by $16 thousand.
EPS
Net loss per basic and diluted share in Q2 2022 was $1.60 million or $0.01 comparable to the previous year when it was $0.87 million or $0.01. The company observed a slight increase in its net loss over the year. The company’s EPS estimates were in-line with the analysts’ expectations.
On September 28, 2021, ISR reported that The American Brachytherapy Society had recognized its Cesium Blu in its consensus statement on the low dose rate of prostate brachytherapy. This was the first time Cesium Blu was included in ABS’s consensus guidelines.
Conclusion
ISR stock is 74% down from the same period of 2021 as the companies were hit by the financial regressions as a result of the pandemic. Recently the company reported positive outcomes from the research of Cesium Blu on the patients. Therefore, it’s stock inclined in Wednesday’s early trading. Also, it expects revenue of $3 million against -$0.01 EPS in the third quarter of 2022.
